These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 22246856)
21. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Tiacci E; Schiavoni G; Martelli MP; Boveri E; Pacini R; Tabarrini A; Zibellini S; Santi A; Pettirossi V; Fortini E; Ascani S; Arcaini L; Inghirami G; Paulli M; Falini B Haematologica; 2013 Apr; 98(4):635-9. PubMed ID: 23349307 [TBL] [Abstract][Full Text] [Related]
22. Phospho-ERK(THR202/Tyr214) is overexpressed in hairy cell leukemia and is a useful diagnostic marker in bone marrow trephine sections. Warden DW; Ondrejka S; Lin J; Durkin L; Bodo J; Hsi ED Am J Surg Pathol; 2013 Feb; 37(2):305-8. PubMed ID: 23211289 [TBL] [Abstract][Full Text] [Related]
24. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. Benlloch S; Payá A; Alenda C; Bessa X; Andreu M; Jover R; Castells A; Llor X; Aranda FI; Massutí B J Mol Diagn; 2006 Nov; 8(5):540-3. PubMed ID: 17065421 [TBL] [Abstract][Full Text] [Related]
25. A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin. Cavalli M; Ilari C; Del Giudice I; Marinelli M; Della Starza I; De Propris MS; De Novi LA; Nunes V; Cafforio L; Raponi S; Mancini F; Mauro FR; Tiacci E; Falini B; Guarini A; Foà R Br J Haematol; 2016 Jul; 174(2):329-31. PubMed ID: 26455504 [No Abstract] [Full Text] [Related]
26. Somatic BRAF-V600E mutations in familial colorectal cancer. Vandrovcova J; Lagerstedt-Robinsson K; Påhlman L; Lindblom A Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2270-3. PubMed ID: 17119056 [TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Capper D; Berghoff AS; Magerle M; Ilhan A; Wöhrer A; Hackl M; Pichler J; Pusch S; Meyer J; Habel A; Petzelbauer P; Birner P; von Deimling A; Preusser M Acta Neuropathol; 2012 Feb; 123(2):223-33. PubMed ID: 22012135 [TBL] [Abstract][Full Text] [Related]
28. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863 [TBL] [Abstract][Full Text] [Related]
29. Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. Broccoli A; Terragna C; Nanni L; Martello M; Armuzzi S; Agostinelli C; Morigi A; Casadei B; Pellegrini C; Stefoni V; Sabattini E; Argnani L; Zinzani PL Hematol Oncol; 2022 Feb; 40(1):57-62. PubMed ID: 34653277 [TBL] [Abstract][Full Text] [Related]
30. BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes. Yap J; Yuan J; Ng WH; Chen GB; Sim YRM; Goh KC; Teo J; Lim TYH; Goay SM; Teo JHJ; Lao Z; Lam P; Sabapathy K; Hu J Mol Cancer; 2023 Aug; 22(1):125. PubMed ID: 37543582 [TBL] [Abstract][Full Text] [Related]
31. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287 [TBL] [Abstract][Full Text] [Related]
32. Requisite analytic and diagnostic performance characteristics for the clinical detection of BRAF V600E in hairy cell leukemia: a comparison of 2 allele-specific PCR assays. Brown NA; Weigelin HC; Bailey N; Laliberte J; Elenitoba-Johnson KS; Lim MS; Betz BL Appl Immunohistochem Mol Morphol; 2015 Sep; 23(8):590-600. PubMed ID: 24503706 [TBL] [Abstract][Full Text] [Related]
33. [Molecular and therapeutic advances in Hairy cell leukemia]. Balsat M; Cornillon J Bull Cancer; 2013 Oct; 100(10):1043-7. PubMed ID: 24103785 [TBL] [Abstract][Full Text] [Related]
34. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. Pelttari H; Schalin-Jäntti C; Arola J; Löyttyniemi E; Knuutila S; Välimäki MJ APMIS; 2012 May; 120(5):380-6. PubMed ID: 22515292 [TBL] [Abstract][Full Text] [Related]